A long-term analysis of the dengue vaccine developed by Butantan reveals that one dose provides at least five years of protection and significantly reduces severe disease cases.
A recent long-term study published in Nature Medicine examined the dengue vaccine developed by the Instituto Butantan, revealing that a single dose provides protection for a minimum of five years. The study involved over 16,000 participants aged between 2 and 59 and found that the overall efficacy of the vaccine was 65% against laboratory-confirmed symptomatic dengue after five years. More remarkably, the vaccine showed an 80.5% efficacy rate against severe dengue cases or instances with alarming signs.
The study's findings demonstrate that the vaccine is effective for individuals regardless of prior dengue infection. Specifically, for participants previously exposed to the dengue virus, the efficacy was reported at 77.1%, while it was slightly lower for those with no previous infections. This information is crucial as it underscores the vaccine's broad applicability in the Brazilian population, which has faced significant dengue challenges.
Dengue remains a public health concern, particularly in tropical regions like Brazil, where conditions favor outbreaks. The results of this study provide valuable insight into the sustained protection offered by the dengue vaccine, potentially guiding public health policies and vaccination campaigns, aiming to reduce the incidence of dengue fever and its severe manifestations across the population.
